With drug giant GlaxoSmithKline (GSK) now stating it will abandon future antidepressant research, one can only wonder if the U.S. Food and Drug Administration noted GSK’s CEO Andrew Witty’s admission that it is “hard to prove that a depression drug is working” because “patient improvement is measured by subjective mood surveys, and not by the clear-cut blood tests and biological measures used in other diseases.”